

	Type	Hits	Search Text	DBs	Time Stamp	Ref #
1	IS&R	2	((("5595997") or ("4659716")).PN.	USPAT	2005/05/18 13:30	S1
2	BRS	21	anhydrous core	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 16:48	S2
3	BRS	1	non-hygrosopic core	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 13:45	S3
4	BRS	1172	inert same film-forming same film same coating	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 13:45	S4
5	BRS	21	inert film-forming same coating	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 13:48	S5
6	BRS	13	inert film-forming same coated	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 13:49	S6
7	BRS	2487	hydroxypropyl methylcellulose same coating	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 13:52	S7
8	IS&R	112726	("514").CLAS.	USPAT	2005/05/18 13:50	S8
9	BRS	675	S7 and S8	USPAT	2005/05/18 13:51	S9
10	BRS	1233	hydroxypropyl methylcellulose near5 (coat or coating or coated)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 13:58	S13
11	BRS	543	hydroxypropyl methylcellulose near3 (coat or coating or coated)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 14:01	S14

	Type	Hits	Search Text	DBs	Time Stamp	Ref #
12	BRS	26	S14 same standard	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 13:55	S15
13	BRS	130	S13 same standard	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 13:55	S16
14	BRS	0	S13 and antihistimine	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 13:56	S17
15	BRS	3	S13 and antihistamine.ab.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 13:56	S18
16	BRS	1590	methylcellulose near5 (coat or coating or coated)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 13:59	S19
17	BRS	1643	standard coating	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 14:01	S20
18	BRS	46	S20 and S8	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 14:01	S21
19	BRS	1281	common coating	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 14:01	S22
20	BRS	26	S22 and S8	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	2005/05/18 14:01	S23

(FILE 'HOME' ENTERED AT 16:52:36 ON 18 MAY 2005)

FILE 'REGISTRY' ENTERED AT 16:52:42 ON 18 MAY 2005

L1 1 S DESCARBOETHOXYLORATADINE

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS, USPATFULL' ENTERED AT 16:53:06 ON  
18 MAY 2005

L2 1317 S DESCARBOETHOXYLORATADINE OR L1  
L3 453 S L2 AND P/DT  
L4 864 S L2 NOT L3  
L5 44 S L3 AND PY<1998  
L6 272 S L2 AND LACTOSE  
L7 270 DUP REM L6 (2 DUPLICATES REMOVED)  
L8 5 S L2 AND LACTOSE-FREE  
L9 5 DUP REM L8 (0 DUPLICATES REMOVED)  
L10 2 S L2 AND (FREE (5W) (LACTOSE OR CARBOHYDRATE))  
L11 9 S SECONDARY (P) AMINE (P) INCOMPATIB? (P) (CARBOHYDRATE OR LACT  
L12 9 DUP REM L11 (0 DUPLICATES REMOVED)

L9 ANSWER 1 OF 5 USPATFULL on STN  
AN 2004:239228 USPATFULL  
TI Compositions and methods for treating colic  
IN Burrell, David, Wake Forest, NC, UNITED STATES  
PI US 2004185032 A1 20040923  
AI US 2003-689539 A1 20031021 (10)  
PRAI US 2003-455417P 20030318 (60)  
DT Utility  
FS APPLICATION  
LREP MCDERMOTT, WILL & EMERY, 600 13th Street, N.W., Washington, DC,  
20005-3096  
CLMN Number of Claims: 41  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1382  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Compositions and methods for providing relief from pain and/or  
discomfort associated with gastrointestinal disorders, including, for  
example, bloating, crying, gas, cramping, regurgitation, diarrhea and  
gastrointestinal pain, associated with colic comprising, at least one  
antiflatulent, at least one histamine H.sub.1-receptor antagonist, and  
optionally, one or more prebiotic and/or one or more probiotic.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 5 USPATFULL on STN  
AN 2002:323075 USPATFULL  
TI Methods for treating vertigo and motion sickness using  
**descarboethoxyloratadine**  
IN McCullough, John R., Worcester, MA, UNITED STATES  
PA Sepracor Inc. (U.S. corporation)  
PI US 2002183241 A1 20021205  
AI US 2002-146415 A1 20020516 (10)  
RLI Continuation of Ser. No. US 1999-272391, filed on 19 Mar 1999, ABANDONED  
Division of Ser. No. US 1997-808116, filed on 28 Feb 1997, GRANTED, Pat.  
No. US 5939426  
DT Utility  
FS APPLICATION  
LREP PENNIE & EDMONDS LLP, 1667 K STREET NW, SUITE 1000, WASHINGTON, DC,  
20006  
CLMN Number of Claims: 34  
ECL Exemplary Claim: 1  
DRWN 1 Drawing Page(s)  
LN.CNT 1156  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Methods for treating urinary incontinence, vertigo and motion sickness  
comprising administering a therapeutically effective amount of  
**descarboethoxyloratadine**, or a pharmaceutically acceptable salt  
thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 5 USPATFULL on STN  
AN 2002:228343 USPATFULL  
TI **Lactose-free**, non-hygroscopic and anhydrous  
pharmaceutical compositions of **descarboethoxyloratadine**  
IN Redmon, Martin P., Marlborough, MA, UNITED STATES  
Butler, Hal T., Marlborough, MA, UNITED STATES  
Wald, Stephen A., Sudbury, MA, UNITED STATES  
Rubin, Paul D., Sudbury, MA, UNITED STATES  
PA SEPRACOR INC., Marlborough, MA, UNITED STATES (U.S. corporation)  
PI US 2002123504 A1 20020905  
AI US 2002-82685 A1 20020225 (10)  
RLI Continuation of Ser. No. US 2000-721088, filed on 22 Nov 2000, ABANDONED  
Continuation of Ser. No. US 1998-19955, filed on 6 Feb 1998, ABANDONED  
PRAI US 1997-53050P 19970721 (60)  
US 1997-45184P 19970430 (60)

US 1997-37325P 19970207 (60)  
DT Utility  
FS APPLICATION  
LREP Candice J. Clement, Heslin Rothenberg Farley & Mesiti P.C., 5 Columbia  
Circle, Albany, NY, 12203  
CLMN Number of Claims: 40  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 995

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Stable pharmaceutical compositions of **descarboethoxyloratadine** (DCL), a metabolic derivative of loratadine, for the treatment of allergic rhinitis and other histamine-induced disorders are disclosed. The compositions are formulated to avoid the incompatibility between DCL and reactive excipients such as lactose and other mono- and di-saccharides. Disclosed compositions include **lactose-free**, non-hygroscopic and anhydrous stable pharmaceutical compositions of DCL.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 5 USPATFULL on STN  
AN 1999:96377 USPATFULL  
TI Methods for treating urinary incontinence using  
**descarboethoxyloratadine**  
IN McCullough, John R., Worcester, MA, United States  
PA Sepracor Inc., Marlborough, MA, United States (U.S. corporation)  
PI US 5939426 19990817  
AI US 1997-808116 19970228 (8)  
DT Utility  
FS Granted

EXNAM Primary Examiner: Moezie, Minna  
LREP Pennie & Edmonds LLP  
CLMN Number of Claims: 7  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Figure(s); 1 Drawing Page(s)  
LN.CNT 1145

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for treating urinary incontinence comprising administering a therapeutically effective amount of **descarboethoxyloratadine**, or a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


L9 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 1998:548533 CAPLUS  
DN 129:180143  
TI **Lactose-free**, non-hygroscopic and anhydrous  
pharmaceutical compositions of **descarboethoxyloratadine**  
IN Redmon, Martin P.; Butler, Hal T.; Wald, Stephen A.; Rubin, Paul D.  
PA Sepracor, Inc., USA  
SO PCT Int. Appl., 34 pp.  
CODEN: PIXXD2

DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9834614	A1	19980813	WO 1998-US2328	19980206
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	TW 522014	B	20030301	TW 1998-87101236	19980203

ZA 9800977	A	19980730	ZA 1998-977	19980206
AU 9862719	A1	19980826	AU 1998-62719	19980206
EP 969836	A1	20000112	EP 1998-904980	19980206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
NZ 335041	A	20000929	NZ 1998-335041	19980206
CA 2267136	C	20001128	CA 1998-2267136	19980206
BR 9806157	A	20010109	BR 1998-6157	19980206
JP 2001511184	T2	20010807	JP 1998-534919	19980206
RU 2209627	C2	20030810	RU 1999-107283	19980206
CN 1132579	B	20031231	CN 1998-802313	19980206
NO 9902157	A	19990504	NO 1999-2157	19990504
US 2002123504	A1	20020905	US 2002-82685	20020225
AU 776837	B2	20040923	AU 2002-45909	20020611
AU 2002045909	A5	20030327		
PRAI US 1997-37325P	P	19970207		
US 1997-45184P	P	19970430		
US 1997-53050P	P	19970721		
AU 1998-62719	A3	19980206		
US 1998-19955	B1	19980206		
WO 1998-US2328	W	19980206		
US 2000-721088	B1	20001122		

GI



I

AB Stable pharmaceutical compns. of **descarboethoxyloratadine** (DCL) (I), a metabolic derivative of loratadine, for the treatment of allergic rhinitis and other histamine-induced disorders are disclosed. The compns. are formulated to avoid the incompatibility between I and reactive excipients such as lactose and other mono- and di-saccharides. Tablets were prepared containing I 10, starch 60, talc 12, acacia 12, and stearic acid 1 mg/tablet.

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 1 OF 9 USPTAFULL on STN  
AN 2003:237907 USPTAFULL  
TI Compositions and methods for the therapy and diagnosis of colon cancer  
IN King, Gordon E., Shoreline, WA, UNITED STATES  
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES  
Xu, Jiangchun, Bellevue, WA, UNITED STATES  
Secrist, Heather, Seattle, WA, UNITED STATES  
Jiang, Yuqiu, Kent, WA, UNITED STATES  
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)  
PI US 2003166064 A1 20030904  
AI US 2002-99926 A1 20020314 (10)  
RLI Continuation-in-part of Ser. No. US 2001-33528, filed on 26 Dec 2001,  
PENDING Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul  
2001, PENDING  
PRAI US 2001-302051P 20010629 (60)  
US 2001-279763P 20010328 (60)  
US 2000-223283P 20000803 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,  
SEATTLE, WA, 98104-7092  
CLMN Number of Claims: 17  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 8531

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,  
particularly colon cancer, are disclosed. Illustrative compositions  
comprise one or more colon tumor polypeptides, immunogenic portions  
thereof, polynucleotides that encode such polypeptides, antigen  
presenting cell that expresses such polypeptides, and T cells that are  
specific for cells expressing such polypeptides. The disclosed  
compositions are useful, for example, in the diagnosis, prevention  
and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 2 OF 9 USPTAFULL on STN  
AN 2003:106233 USPTAFULL  
TI Compositions and methods for the therapy and diagnosis of pancreatic  
cancer  
IN Benson, Darin R., Seattle, WA, UNITED STATES  
Kalos, Michael D., Seattle, WA, UNITED STATES  
Lodes, Michael J., Seattle, WA, UNITED STATES  
Persing, David H., Redmond, WA, UNITED STATES  
Hepler, William T., Seattle, WA, UNITED STATES  
Jiang, Yuqiu, Kent, WA, UNITED STATES  
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)  
PI US 2003073144 A1 20030417  
AI US 2002-60036 A1 20020130 (10)  
PRAI US 2001-333626P 20011127 (60)  
US 2001-305484P 20010712 (60)  
US 2001-265305P 20010130 (60)  
US 2001-267568P 20010209 (60)  
US 2001-313999P 20010820 (60)  
US 2001-291631P 20010516 (60)  
US 2001-287112P 20010428 (60)  
US 2001-278651P 20010321 (60)  
US 2001-265682P 20010131 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,  
SEATTLE, WA, 98104-7092  
CLMN Number of Claims: 17  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 14253

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly pancreatic cancer, are disclosed. Illustrative compositions comprise one or more pancreatic tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly pancreatic cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 3 OF 9 USPATFULL on STN

AN 2003:17986 USPATFULL

TI STABLE DOSAGE FORMS OF FLUOXETINE AND ITS ENANTIOMERS

IN REDMON, MARTIN P., MARLBOROUGH, MA, UNITED STATES

BUTLER, HAL T., MARLBOROUGH, MA, UNITED STATES

WALD, STEPHEN A., MARLBOROUGH, MA, UNITED STATES

PI US 2003013740 A1 20030116

AI US 1998-49227 A1 19980327 (9)

DT Utility

FS APPLICATION

LREP PENNIE & EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711

CLMN Number of Claims: 35

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1306

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Chemically and physically stable pharmaceutical formulations, of the potent antidepressant, fluoxetine, its enantiomers and salts.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 4 OF 9 USPATFULL on STN

AN 2002:308396 USPATFULL

TI Pharmaceutical compositions comprising norastemizole

IN Redmon, Martin P., Oxford, MA, UNITED STATES

Butler, Hal T., Marlborough, MA, UNITED STATES

Wald, Stephen A., Sudbury, MA, UNITED STATES

PI US 2002173522 A1 20021121

AI US 2002-75616 A1 20020215 (10)

RLI Continuation-in-part of Ser. No. US 2000-719843, filed on 21 Nov 2000, ABANDONED A 371 of International Ser. No. WO 1998-US5701, filed on 25 Mar 1998, UNKNOWN Continuation-in-part of Ser. No. US 1997-851786, filed on 6 May 1997, ABANDONED Continuation-in-part of Ser. No. US 1997-824477, filed on 26 Mar 1997, ABANDONED Continuation-in-part of Ser. No. US 2000-721711, filed on 27 Nov 2000, ABANDONED Continuation-in-part of Ser. No. US 1997-851786, filed on 6 May 1997, ABANDONED Continuation-in-part of Ser. No. US 1997-824477, filed on 26 Mar 1997, ABANDONED

DT Utility

FS APPLICATION

LREP PENNIE & EDMONDS LLP, 1667 K STREET NW, SUITE 1000, WASHINGTON, DC, 20006

CLMN Number of Claims: 40

ECL Exemplary Claim: 1

DRWN 2 Drawing Page(s)

LN.CNT 1736

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to chemically stable pharmaceutical formulations of the potent antihistamine, norastemizole. The compositions can include norastemizole, or a pharmaceutically acceptable salt thereof; a diluent; a binder; a disintegrant; and a lubricant or the compositions can include particles of norastemizole, or a pharmaceutically acceptable salt thereof, coated with an inert coating and a pharmaceutically acceptable excipient. The present invention also relates to methods of treating allergic disorders.



CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 5 OF 9 USPATFULL on STN  
AN 2002:272801 USPATFULL  
TI Compositions and methods for the therapy and diagnosis of colon cancer  
IN Stolk, John A., Bothell, WA, UNITED STATES  
Xu, Jiangchun, Bellevue, WA, UNITED STATES  
Chenault, Ruth A., Seattle, WA, UNITED STATES  
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES  
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)  
PI US 2002150922 A1 20021017  
AI US 2001-998598 A1 20011116 (9)  
PRAI US 2001-304037P 20010710 (60)  
US 2001-279670P 20010328 (60)  
US 2001-267011P 20010206 (60)  
US 2000-252222P 20001120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,  
SEATTLE, WA, 98104-7092  
CLMN Number of Claims: 17  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 9233

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,  
particularly colon cancer, are disclosed. Illustrative compositions  
comprise one or more colon tumor polypeptides, immunogenic portions  
thereof, polynucleotides that encode such polypeptides, antigen  
presenting cell that expresses such polypeptides, and T cells that are  
specific for cells expressing such polypeptides. The disclosed  
compositions are useful, for example, in the diagnosis, prevention  
and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 6 OF 9 USPATFULL on STN  
AN 2002:243051 USPATFULL  
TI Compositions and methods for the therapy and diagnosis of ovarian cancer  
IN Algate, Paul A., Issaquah, WA, UNITED STATES  
Jones, Robert, Seattle, WA, UNITED STATES  
Harlocker, Susan L., Seattle, WA, UNITED STATES  
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)  
PI US 2002132237 A1 20020919  
AI US 2001-867701 A1 20010529 (9)  
PRAI US 2000-207484P 20000526 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,  
SEATTLE, WA, 98104-7092  
CLMN Number of Claims: 11  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 25718

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,  
particularly ovarian cancer, are disclosed. Illustrative compositions  
comprise one or more ovarian tumor polypeptides, immunogenic portions  
thereof, polynucleotides that encode such polypeptides, antigen  
presenting cell that expresses such polypeptides, and T cells that are  
specific for cells expressing such polypeptides. The disclosed  
compositions are useful, for example, in the diagnosis, prevention  
and/or treatment of diseases, particularly ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 7 OF 9 USPATFULL on STN  
AN 2002:242791 USPATFULL

TI . Compositions and methods for the therapy and diagnosis of colon cancer  
IN King, Gordon E., Shoreline, WA, UNITED STATES  
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES  
Xu, Jiangchun, Bellevue, WA, UNITED STATES  
Secrist, Heather, Seattle, WA, UNITED STATES  
PA Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)  
PI US 2002131971 A1 20020919  
AI US 2001-33528 A1 20011226 (10)  
RLI Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul 2001,  
PENDING  
PRAI US 2001-302051P 20010629 (60)  
US 2001-279763P 20010328 (60)  
US 2000-223283P 20000803 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,  
SEATTLE, WA, 98104-7092  
CLMN Number of Claims: 17  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 8083

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer,  
particularly colon cancer, are disclosed. Illustrative compositions  
comprise one or more colon tumor polypeptides, immunogenic portions  
thereof, polynucleotides that encode such polypeptides, antigen  
presenting cell that expresses such polypeptides, and T cells that are  
specific for cells expressing such polypeptides. The disclosed  
compositions are useful, for example, in the diagnosis, prevention  
and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 8 OF 9 USPATFULL on STN  
AN 2001:25463 USPATFULL  
TI Stabilized thyroxine medications  
IN Groenewoud, Pieter J., 4 Westover Ct., Yardley, PA, United States 19067  
PI US 6190696 B1 20010220  
AI US 1999-327256 19990607 (9)  
RLI Continuation-in-part of Ser. No. US 1998-92819, filed on 8 Jun 1998, now  
abandoned  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Channavajjala,  
Lakshmi  
LREP Wobensmith, III, Zachary T.  
CLMN Number of Claims: 8  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 725

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Thyroxine medications which include combinations of levothyroxine,  
and/or liothronine, or dextrothyroxine, or thyroid, and one or more  
iodine salts, or iodine donor compounds are described, which produce a  
stable thyroxine medication, with a long shelf life. A method for  
manufacturing the medications is also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 1970:136347 CAPLUS  
DN 72:136347  
TI Incompatibility of lactoses and amines  
AU Ritschel, W. A.; Ritschel-Beurlin, Gerda  
CS Coll. of Pharm., Univ. of Cincinnati, Cincinnati, OH, USA  
SO Praeparative Pharmazie (1970), 6(2), 21-8  
CODEN: PPKKBD; ISSN: 0370-1220  
DT Journal

LA German

AB Thirty-two different amines were investigated for their incompatibility with lactose alone and with lactose with Mg stearate or stearic acid. All the amines gave a discoloration at least in one of the prepns. after 8-weeks storage in a hygrostat at 95% relative humidity and 40°. The discolorations occurred earlier and to a greater extent in tablets (pressed mixts.) than in powders. A dependence of the discoloration on the kind of amine (primary, secondary, tertiary, quaternary) and on the change of pH could not be found.